Roche (OTCMKTS:RHHBY) Stock Rating Lowered by Deutsche Bank Aktiengesellschaft

Roche (OTCMKTS:RHHBY) was downgraded by equities researchers at Deutsche Bank Aktiengesellschaft from a “hold” rating to a “sell” rating in a report released on Friday, MarketBeat.com reports.

A number of other analysts have also issued reports on the company. Bank of America upgraded Roche from a “neutral” rating to a “buy” rating in a report on Friday. The Goldman Sachs Group started coverage on Roche in a research note on Thursday, May 30th. They issued a “sell” rating for the company. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold”.

Roche Stock Performance

RHHBY stock opened at $39.11 on Friday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.04 and a current ratio of 1.35. Roche has a 52-week low of $29.20 and a 52-week high of $42.43. The company’s 50 day simple moving average is $39.59 and its 200-day simple moving average is $34.84.

Hedge Funds Weigh In On Roche

Several institutional investors and hedge funds have recently modified their holdings of RHHBY. AlphaMark Advisors LLC bought a new stake in Roche in the first quarter worth $34,000. GAMMA Investing LLC boosted its holdings in Roche by 61.5% in the second quarter. GAMMA Investing LLC now owns 5,038 shares of the company’s stock worth $175,000 after purchasing an additional 1,919 shares in the last quarter. Archer Investment Corp boosted its holdings in Roche by 10.6% in the second quarter. Archer Investment Corp now owns 6,810 shares of the company’s stock worth $236,000 after purchasing an additional 652 shares in the last quarter. Waldron Private Wealth LLC bought a new stake in Roche in the second quarter worth $263,000. Finally, Lee Danner & Bass Inc. bought a new stake in Roche in the second quarter worth $327,000.

Roche Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.